Dexamethasone Delivery via Amphiphilic, Low‐swelling Hydrogels Treats Postoperative Inflammation in Cervical Spine Applications
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202404292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Stephen W Linderman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332-0363, USA. Hauptthemen laut MEDLINE: Dexamethasone, Hydrogels, Inflammation, Cervical Vertebrae. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS, Biolocity, the Georgia Research Alliance, and in kind support from T3 Labs, Global Center for Medtech Innovation (GCMI), and Georgia Institute of Technology.
Abstract (Originalsprache)
Anterior cervical spine surgeries are often complicated by difficulty swallowing due to local postoperative swelling, pain, scarring, and tissue dysfunction. These postoperative events lead to systemic steroid and narcotic use. Local, sustained drug delivery may address these problems, but current materials are unsafe for tight surgical spaces due to high biomaterial swelling, especially upon degradation. To address these shortcomings, a low‐swelling, amphiphilic hydrogel system termed DexaPatch is developed containing dexamethasone‐poly(lactic‐co‐glycolic acid) (PLGA) microparticles for sustained release upon local implantation in the surgical site. The bulk amphiphilic hydrogel, comprised of 4‐arm poly(ethylene glycol) (PEG)‐maleimide macromer cross‐linked with triblock dithiolated PEG‐poly(propylene glycol)‐PEG (poloxamer a.k.a. Pluronic), achieves consistent and tunable mechanical and low‐swelling properties. Dexamethasone is released in a burst, followed by a sustained release over 40 days, similar to the release from microparticles alone. The DexaPatch system is lyophilized for shelf stability and surgical handling properties, sterilized, and briefly rehydrated in the operating room prior to surgical implantation in a rabbit model of anterior spinal surgery. DexaPatch results in significantly reduced prevertebral edema radiographically and decreased fibrosis in prevertebral muscles compared to sham surgery. This implantable biomaterial platform reduces local postoperative inflammation with potential surgical applications throughout the body.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332-0363, USA.
- Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, 30322, USA.
ORCID-Profile: Andrés J García
Förderung
- NIGMS NIH HHS
- NHLBI NIH HHS
- Biolocity, the Georgia Research Alliance, and in kind support from T3 Labs, Global Center for Medtech Innovation (GCMI), and Georgia Institute of Technology
- National Heart, Lung, and Blood Institute
Zitieren
APA
Linderman, S. W., Barber, G. F., DeVeaux, S. A., Botchwey, E. A., Refai, D., Klein, A. M., & García, A. J. (2025). Dexamethasone Delivery via Amphiphilic, Low‐swelling Hydrogels Treats Postoperative Inflammation in Cervical Spine Applications. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404292
Vancouver
Linderman SW, Barber GF, DeVeaux SA, Botchwey EA, Refai D, Klein AM, et al. Dexamethasone Delivery via Amphiphilic, Low‐swelling Hydrogels Treats Postoperative Inflammation in Cervical Spine Applications. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404292
BibTeX
@article{Linderman2025,
author = {Linderman, Stephen W and Barber, Graham F and DeVeaux, S'Dravious A and Botchwey, Edward A and Refai, Daniel and Klein, Adam M and García, Andrés J},
title = {Dexamethasone Delivery via Amphiphilic, Low‐swelling Hydrogels Treats Postoperative Inflammation in Cervical Spine Applications},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202404292}
}
EUVIMED